What role does stereotactic ablative radiotherapy have in advanced castrate-resistant prostate cancer?

被引：2
|
作者：
Phillips, Ryan [1 ]
Ost, Piet [2 ]
Tran, Phuoc T. [1 ,3 ,4 ]
机构：
[1] Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21218 USA
[2] Univ Ghent, Dept Radiat Oncol & Expt Canc Res, Ghent, Belgium
[3] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21218 USA
[4] Johns Hopkins Univ, Dept Urol, Baltimore, MD 21218 USA
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 24期
关键词：
castration-resistant prostate cancer; neoplasm metastasis; neoplasm recurrence; oligometastasis; prostate cancer; stereotactic ablative radiotherapy; stereotactic body radiation therapy; ANDROGEN DEPRIVATION; BODY RADIOTHERAPY; LUNG-CANCER; THERAPY; HISTORY;
D O I：
10.2217/fon-2017-0337
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2121 / 2124
页数：4
相关论文
共 50 条
  • [41] Implementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?
    Mottet, Nicolas
    Clarke, Noel
    De Santis, Maria
    Zattoni, Filiberto
    Morote, Juan
    Joniau, Steven
    BJU INTERNATIONAL, 2015, 115 (03) : 364 - 372
  • [42] New Therapeutics to Treat Castrate-Resistant Prostate Cancer
    Acar, Omer
    Esen, Tarik
    Lack, Nathan A.
    SCIENTIFIC WORLD JOURNAL, 2013,
  • [43] Incidence of dural metastases in castrate-resistant prostate cancer
    Khondker, Adree
    Kwong, Jethro C. C.
    Tran, Christopher
    Evans, Emily
    Aditya, Ishan
    Raveendran, Lucshman
    Chen, Yingming A.
    Ali, Amna
    Feifer, Andrew
    JOURNAL OF CLINICAL UROLOGY, 2024, 17 (04) : 378 - 385
  • [44] Changing Therapeutic Paradigms in Castrate-Resistant Prostate Cancer
    Zivi, Andrea
    Massard, Christophe
    De-Bono, Johann
    CLINICAL GENITOURINARY CANCER, 2010, 8 (01) : 17 - 22
  • [45] Symptom Clusters in Men With Castrate-Resistant Prostate Cancer
    Vayne-Bossert, Petra
    Hardy, Janet
    Skerman, Helen
    Yates, Patsy
    Sullivan, Karyn
    Good, Phillip
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2017, 54 (03) : E1 - E3
  • [46] The role of macrophages in docetaxel (DTX) resistance in castrate-resistant prostate cancer (CRPC).
    Horvath, Lisa
    Chatfield, Mark D.
    Lee-Ng, Michelle
    Lin, Hui-Ming
    Castillo, Lesley
    Breit, Samuel N.
    Brown, David A.
    Molloy, Mark P.
    Marx, Gavin M.
    Pavlakis, Nick
    Boyer, Michael J.
    Stockier, Martin R.
    Wykes, Richard
    Henshall, Susan M.
    Mahon, Kate Lynette
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [47] Phase II Trial of Sipuleucel-T and Stereotactic Ablative Radiation therapy (SAbR) for Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Dohopolski, M.
    Watumull, L.
    Mathews, D.
    Gao, A.
    Garant, A.
    Choy, H.
    Ahn, C.
    Timmerman, R. D.
    Courtney, K.
    Hannan, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E879 - E879
  • [48] New horizons in the management of castrate-resistant prostate cancer
    Kamel, Mohamed H.
    Raheem, Omer A.
    Davis, Rodney
    JOURNAL OF CLINICAL UROLOGY, 2018, 11 (04) : 258 - 265
  • [49] There Is No Current Role for Molecular Phenotyping in Metastatic Castrate-Resistant Prostate Cancer (cont)
    Vogelzang, Nicholas J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (09) : 584 - 585
  • [50] Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer
    Dayyani, Farshid
    Gallick, Gary E.
    Logothetis, Christopher J.
    Corn, Paul G.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (22): : 1665 - 1675
12345